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Viral vectors represent an attractive technology for vaccine delivery. We exploited the integrase defective lentiviral vector (IDLV)
as a platform for delivering relevant antigens within the context of the ADITEC collaborative research program. In particular,
Influenza virus hemagglutinin (HA) and nucleoprotein (NP) were delivered by IDLVs while H1N1 A/California/7/2009 subunit vaccine
(HAp) with or without adjuvant was used to compare the immune response in a murine model of immunization. In order to
maximize the antibody response against HA, both IDLVs were also pseudotyped with HA (IDLV-HA/HA and IDLV-NP/HA, respectively).
Groups of CB6F1 mice were immunized intramuscularly with a single dose of IDLV-NP/HA, IDLV-HA/HA, HAp alone or with HAp
together with the systemic adjuvant MF59. Six months after the vaccine prime all groups were boosted with HAp alone. Cellular
and antibody responses to influenza antigens were measured at different time points after the immunizations. Mice immunized
with HA-pseudotyped IDLVs showed similar levels of anti-H1N1 IgG over time, evaluated by ELISA, which were comparable to those
induced by HAp+MF59 vaccination, but significantly higher than those induced by HAp alone. The boost with HAp alone induced an
increase of antibodies in all groups, and the responses were maintained at higher levels up to 18 weeks post-boost. The antibody
response was functional and persistent overtime, capable of neutralizing virus infectivity, as evaluated by hemagglutination
inhibition and microneutralization assays. Moreover, since neuraminidase (NA)-expressing plasmid was included during IDLV
preparation, immunization with IDLV-NP/HA and IDLV-HA/HA also induced functional anti-NA antibodies, evaluated by Enzyme-Linked
Lectine Assay (ELLA). IFNγ‐ELISPOT showed evidence of HA‐specific response in IDLV‐HA/HA immunized animals and persistent
NP-specific CD8+ T cell response in IDLV-NP/HA immunized mice. Taken together our results indicate that IDLV can be harnessed for
producing a vaccine able to induce a comprehensive immune response, including functional antibodies directed towards HA and NA
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Viral vectors represent an attractive technology for vaccine delivery. We exploited the integrase 3 
defective lentiviral vector (IDLV) as a platform for delivering relevant antigens within the context of 4 
the ADITEC collaborative research program. In particular, Influenza virus hemagglutinin (HA) and 5 
nucleoprotein (NP) were delivered by IDLVs while H1N1 A/California/7/2009 subunit vaccine 6 
(HAp) with or without adjuvant was used to compare the immune response in a murine model of 7 
immunization. In order to maximize the antibody response against HA, both IDLVs were also 8 
pseudotyped with HA (IDLV-HA/HA and IDLV-NP/HA, respectively). Groups of CB6F1 mice were 9 
immunized intramuscularly with a single dose of IDLV-NP/HA, IDLV-HA/HA, HAp alone or with 10 
HAp together with the systemic adjuvant MF59. Six months after the vaccine prime all groups were 11 
boosted with HAp alone. Cellular and antibody responses to influenza antigens were measured at 12 
different time points after the immunizations. Mice immunized with HA-pseudotyped IDLVs showed 13 
similar levels of anti-H1N1 IgG over time, evaluated by ELISA, which were comparable to those 14 
induced by HAp+MF59 vaccination, but significantly higher than those induced by HAp alone. The 15 
boost with HAp alone induced an increase of antibodies in all groups, and the responses were 16 
maintained at higher levels up to 18 weeks post-boost. The antibody response was functional and 17 
persistent overtime, capable of neutralizing virus infectivity, as evaluated by hemagglutination 18 
inhibition and microneutralization assays. Moreover, since neuraminidase (NA)-expressing plasmid 19 
was included during IDLV preparation, immunization with IDLV-NP/HA and IDLV-HA/HA also 20 
induced functional anti-NA antibodies, evaluated by Enzyme-Linked Lectine Assay (ELLA). IFNγ-21 
ELISPOT showed evidence of HA-specific response in IDLV-HA/HA immunized animals and 22 
persistent NP-specific CD8+ T cell response in IDLV-NP/HA immunized mice. Taken together our 23 
results indicate that IDLV can be harnessed for producing a vaccine able to induce a comprehensive 24 
immune response, including functional antibodies directed towards HA and NA proteins present on 25 
the vector particles in addition to a functional T cell response directed to the protein transcribed from 26 
the vector. 27 
 28 
 29 
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Improvements on existing delivery systems are a significant aspect to be considered in order to obtain 3 
more effective vaccines. Viral vectors represent an attractive platform for vaccine development due 4 
to their ability to effectively deliver antigens of interest into cells and to generate humoral and cellular 5 
mediated immune responses against the encoded transgenes. Integrase defective lentiviral vectors 6 
(IDLVs) represent a promising platform for immunogen delivery for vaccination purposes (1, 2). 7 
IDLVs are self-inactivating, non-integrating and non-replicating vectors with high transduction 8 
efficiency both in vitro and in vivo. In contrast to parental lentiviral vector (LV), IDLV are produced 9 
by incorporating a mutated form of the Integrase protein in the recombinant LV, preventing integration 10 
and overcoming the risk of insertional mutagenesis. The loss of integration has been demonstrated in 11 
several murine models in vivo and in vitro (3). In the absence of integration, transgene expression is 12 
due to the unintegrated circular forms of the vector, which are maintained episomally in the target 13 
cells in the absence of cell division (4, 5). Only the transgene of interest is expressed from episomal 14 
IDLV in the absence of any other parental viral product. Dendritic cells and macrophages, the main 15 
cell types mediating the immune response, are non-dividing cells that are readily transduced by IDLV, 16 
eliciting the expansion of antigen-specific T cells (6, 7). 17 
 18 
Over the course of the past decade, several reports have shown that a single immunization with IDLV-19 
vectored antigens induces a persistent immune response both in murine and simian models of 20 
immunization (1, 2, 8). Antigen presentation persisted for at least 30 days from immunization (9), 21 
suggesting that prolonged expression might be a unique characteristic of IDLV in vivo. In preclinical 22 
challenge experiments, a single immunization with IDLV expressing human papillomavirus (HPV)-23 
E7 tumor specific antigen resulted in eradication of established tumors in mice, validating the ability 24 
to induce an effective T cell response (10). Administration of IDLV encoding antigens in murine 25 
models of West Nile Virus and malaria induced protective antibodies when challenged with the 26 
respective pathogens (11, 12). IDLV expressing the influenza virus nucleoprotein (NP) was protective 27 
against homologous and heterosubtypic influenza virus challenge (13). More recently we showed that 28 
immunization of rhesus macaques with IDLV expressing HIV-Env 1086.C gp140 induced broad and 29 
sustained immune responses up to 1 year from the immunization (8). Importantly, IDLV is under 30 
evaluation in clinical trials for cancer immunotherapy (ClinicalTrials.gov Identifier numbers: 31 
NCT02609984, NCT02122861, NCT02387125). 32 
 33 
In addition to the potential for inducing a prolonged immune response due to expression of the 34 
vectored transgene from episomal DNA circles, IDLV can be harnessed as a cargo for delivering 35 
immunogens after incorporation into the vector’s particles. This can be accomplished by fusion of 36 
foreign antigens with proteins incorporated into the lentiviral particles during particle assembly (14, 37 
15) or via pseudotyping. Pseudotyping with heterologous viral glycoprotein envelopes is always used 38 
during LV production for allowing transduction of target cells or tissues (16). LV particles can be 39 
pseudotyped with a wide range of heterologous viral envelope proteins, including Influenza virus 40 
hemagglutinin (HA) (17-19). Recovered particles gain the tropism of the virus from which the 41 
envelope glycoprotein was derived. The most widely used envelope glycoprotein for pseudotyping 42 
LV is the vesicular stomatitis G glycoprotein (VSV.G), which allow broad and efficient transduction 43 
of target cells in vitro and in vivo (20). Importantly, the envelope glycoprotein displayed on the surface 44 
of the particles can elicit humoral immune responses that can be protective in animal models of 45 
immunizations (21-23). 46 
 47 
Seasonal influenza A virus (IAV) infections cause significant morbidity and mortality worldwide and 48 
remain a major public health concern (24, 25). Currently licensed influenza vaccines elicit 49 
neutralizing antibodies (Abs) targeting HA, preventing influenza virus entry into cells (26). In 50 





component contained in the annual vaccine formulations (27). However, seasonal vaccines do not 1 
protect against new mismatched strains and require frequent reformulation based on the prediction of 2 
strains that may circulate (27). Conversely, cell-mediated immunity targeting conserved antigens, 3 
such as influenza nucleoprotein (NP), is cross reactive and, although T cell immunity is unable to 4 
prevent disease, may contribute to improved clearance and decreased symptoms (28-30). NP is 90% 5 
conserved among influenza virus strains (31), and it is the major target of the cross-protective T cell 6 
response against influenza virus in the mouse model (32-35). However, while protection from 7 
influenza challenge in mice can be achieved in presence of NP-specific T cell responses (36), an 8 
efficient influenza vaccine for humans should be able to generate a more comprehensive and durable 9 
immune response in terms of both protective antibodies and effective T cells. 10 
To this aim,Iin the present study we evaluated the immune response induced by a multi-antigen 11 
IDLV-based influenza vaccine pseudotyped with HA protein from A/California/7/09 (H1N1-pdm09) 12 
virus and expressing either influenza HA or NP proteins as transgenes. Results indicated that a single 13 
immunization with multivalent IDLVs induced persistent and effective antiviral Abs and T cell 14 
responses directed towards HA or NP transgenes. 15 
 16 





MATERIALS AND METHODS 1 
 2 
Vector construction. The self-inactivating (SIN) lentiviral transfer vector plasmid pTY2-NP 3 
expressing the nucleprotein (NP, GenBank: AAM75159.1) from Influenza virus A/PR/8/1934 4 
(H1N1) has been already described (13). For construction of SIN lentiviral transfer vector plasmid 5 
pGAE-HA expressing the hemagglutinin (HA, GenBank: ACP44189.1) from influenza virus 6 
A/California/7/2009 (H1N1), the codon optimized HA open reading frame (ORF) was chemically 7 
synthesized, inserted into pUC57 plasmid (TwinHelix, Milan, Italy), excised with AgeI/SalI 8 
restriction enzymes and cloned into pGAE-GFP lentiviral transfer vector (376) by replacing the green 9 
fluorescent protein (GFP) coding sequence. The Integrase (IN) defective packaging plasmid, 10 
producing the viral proteins necessary for vector particle production, and the phCMV-VSV.G 11 
plasmid, encoding the pseudotyping vesicular stomatitis virus envelope glycoprotein G (VSV.G) 12 
from Indiana serotype, necessary for IDLV entry into target cells, have been previously described 13 
(387, 398). Plasmids pCAGGS-TMPRSS2 and pCAGGS-HAT, expressing the transmembrane 14 
protease serine 2 (TMPRSS2, GenBank: U75329) and the human airway trypsin (HAT, GenBank: 15 
AB002134) proteins respectively, were described previously (4039). Plasmids pCMV3-H1N1-C-NA 16 
(Sino Biological Inc., North Wales, PA, USA), expressing the Neuraminidase (NA, GenBank: 17 
ACP41107.1) derived from influenza virus A/California/4/2009 (H1N1), and  pCMV-HACal09, 18 
expressing the codon optimized HA protein from the CMV promoter, were used during production 19 
of HA-pseudotyped IDLV-NP/HA. 20 
 21 
Production of lentiviral vectors. Lenti-X human embryonic kidney 293T cell line was obtained 22 
from Clontech (Mountain View, CA, USA) and was used for IDLV production following established 23 
protocols (410). Cells were maintained in Dulbecco’s Modified Eagles (DMEM) (Gibco, Life 24 
Technologies Italia, Monza, Italy) supplemented with 10% fetal calf serum (Corning, Mediatech inc. 25 
Manassas, VA, USA) and 100 units/ml penicillin/streptomycin/glutamine (PSG) (Gibco, Life 26 
Technologies Italia, Monza, Italy). For production of IDLVs pseudotyped with HA and expressing 27 
either HA (IDLV-HA/HA) or NP (IDLV-NP/HA), 3.5 x 106 293T Lenti-X cells were seeded on 10-28 
cm Petri dishes (Corning Incorporated - Life Sciences, Oneonta, NY, USA) and incubated overnight. 29 
Cells were transiently transfected with lentiviral transfer vector expressing influenza HA or NP, along 30 
with IN defective packaging and VSV.G-envelope plasmids by Calcium Phosphate using the 31 
Profection Mammalian Transfection System (Promega Corporation, Madison, WI) as previously 32 
described (13, 398, 410).  Plasmids pCAGGS-TMPRSS2 or pCAGGS-HAT and plasmid pCMV3-33 
H1N1-C-NA were included to express protease and NA during IDLV production. To pseudotype 34 
IDLV-NP/HA with HA protein, pCMV-HACal09 plasmid was added during IDLV-NP/HA 35 
production. After 48 and 72 hrs post-transfection, cell culture supernatants were collected, cleared 36 
from cellular debris by low-speed centrifugation and passed through a 0.45-µm pore size filter 37 
(Millipore Corporation, Billerica, MA). To produce IDLV stocks for mouse immunization, vector 38 
containing supernatants were concentrated by ultracentrifugation (Beckman Coulter, Fullerton, CA) 39 
on a 20% sucrose gradient (Sigma Chemical Co., St. Louis, MO) at 23.000 rpm for 2.5 hrs at 4°C 40 
using a SW28 swinging bucket rotor (Beckman). Pelleted vector particles were resuspended in 1X 41 
phosphate-buffered saline (Gibco, Life Technologies Italia, Monza, Italy) and stored at -80°C until 42 
use. Each IDLV-HA/HA or IDLV-NP/HA stock was titred by the reverse transcriptase (RT) activity 43 
assay and the corresponding transducing units (TU) were calculated by comparing the RT activity to 44 
the one of IDLV-GFP virions with known infectious titers, thus allowing for the determination of 45 
their infectious titer units (421). 46 
 47 
Flow Cytometry and Confocal laser scanning microscopy (CLSM). 293T Lenti-X cells were 48 
plated in 6-well microplates for flow cytometry analysis or seeded in 24-well cluster plates onto 12-49 
mm cover glasses previously treated with L-polylysine (SIGMA) for CLSM. Cells were then 50 





Transfection System (Promega). Twenty-four hours following transfection, non-permeabilized cells 1 
were stained with antiserum from CB6F1 mice immunized with purified H1N1 subunit vaccine 2 
(0.1µg of HA per dose) from influenza strain H1N1 A/California/7/2009 (provided by Novartis 3 
Vaccine & Diagnostics Srl, Siena, Italy) in the presence of MF59 adjuvant (provided by Novartis). 4 
After 45 minutes cells were washed in PBS 1X  and then incubated for 30 minutes with secondary 5 
antibody PE Goat anti-mouse IgG (Biolegend, San Diego, CA, USA), for flow cytometry analysis, 6 
or Alexa Fluor-488- F(ab’)2 fragments of goat anti-mouse (Molecular Probes, Life Technologies, 7 
Carlsbad, CA, USA), for CSLM analysis. For flow cytometry cells were fixed with 1% 8 
paraformaldehyde and fluorescence was measured using the FACScalibur (BD Biosciences, Milan, 9 
Italy), and data were analyzed using CellQuest (BD Biosciences). For CLSM, cells were fixed with 10 
methanol and the coverslips were mounted with Vectashield® antifade mounting medium containing 11 
DAPI (Vector Labs, Burlingame, CA, USA) on the microscope slides. CLSM observations were 12 
performed on a Leica TCS SP2 AOBS apparatus (Leica Microsystems, Wetzlar, Germany), using 13 
excitation spectral laser lines at 405nm and 488nm, using the confocal software (Leica, Wetzlar, 14 
Germany) and Photoshop CS5 (Adobe Systems, San Jose, CA, USA). Signals from different 15 
fluorescent probes were taken in sequential scanning mode, several fields were analyzed for each 16 
labeling condition, and representative results are shown. Images represented a single central optical 17 
section taken in the center of each cell nucleus and a 3D reconstruction. 18 
 19 
Western blot. To evaluate HA presence on IDLV particles, pellets of IDLV concentrated 20 
preparations were resuspended in SDS loading buffer. Lysed virions were separated on 12% SDS 21 
polyacrylamide gel under reducing conditions and transferred to a nitrocellulose membrane (Sartorius 22 
Stedim Italy).  Filters were saturated for 2 hr with 5% nonfat dry milk (NFDM) in PBST (PBS with 23 
0.1% Tween 20) and then incubated with HA antiserum for 1 hr at room temperature followed by 24 
incubation for 1 hr at room temperature with an anti-mouse HRP-conjugated IgG (Sigma Aldrich, 25 
Milan, Italy). The immunocomplexes were visualized using chemiluminescence ECL detection 26 
system (Luminata Forte Western HRP Substrate, Millipore). H1N1 subunit vaccine from 27 
A/California/7/2009 virus was used as positive control. 28 
 29 
Mice and immunization schedule 30 
Ethics statement. Animals were maintained under specific pathogen-free conditions in the animal 31 
facilities at the Istituto Superiore di Sanità (ISS) and treated according to European Union guidelines 32 
and Italian legislation (Decreto Legislativo 26/2014). All animal studies were authorized by the 33 
Italian Ministry of Healthy and reviewed by the Service for Animal Welfare at ISS (Authorization n. 34 
314/2015-PR of 30/04/2015). All animals were euthanized by CO2 inhalation using approved 35 
chambers, and efforts were made to minimize suffering and discomfort.  36 
 37 
CB6F1 female mice were purchased from Harlan (Harlan Laboratory, Srl, San Pietro al Natisone, 38 
Italy). Six- to eight-week-old CB6F1 mice, four mice per group, were injected once intramuscularly 39 
in the thigh with (i) 1 x 107 RT units/mouse of IDLV-HA/HA, (ii) 1 x 107 RT units/mouse of IDLV-40 
NP/HA, (iii) H1N1 A/California/7/2009 (0.1 µg/mouse of HA protein, henceforth referred to as HAp) 41 
alone and (iv) 0.1 µg/mouse of HAp in presence of MF59 adjuvant (HAp+MF59). Naïve, non-42 
immunized mice were kept for parallel analysis. All immunized mice were boosted with HAp alone 43 
24 weeks after the prime. Antibodies (Abs) were measured in serum at different time points, starting 44 
from 2 weeks after the prime and up to 18 weeks after the boost. The cellular immune responses were 45 
analyzed at 4, 12 and 24 weeks after the prime in blood samples and in splenocytes at sacrifice (18 46 
weeks after the boost).  47 
Serum samples were obtained from blood collected from the retro-orbital plexus of mice with glass 48 
Pasteur pipettes and stored at -20°C until assayed. Heparin-treated glass Pasteur pipettes were used 49 
to collect blood in order to perform IFNγ ELISPOT assay. Leukocytes, obtained after Ammonium 50 





(Gibco) containing 10% fetal bovine serum (FBS) (Lonza, Treviglio, Milan, Italy), 100 units/ml of 1 
PSG (Gibco), non-essential aminoacids (Gibco), sodium pyruvate 1 mM (Gibco), HEPES buffer 2 
solution 25 mM (Gibco) 50 mM 2-mercaptoethanol (Sigma Chemicals). Splenocytes were prepared 3 
by mechanical disruption and passage through cell strainers (BD Biosciences) and resuspended in 4 
complete RPMI medium, as previously described (398). 5 
 6 
IFNγ ELISPOT  7 
The IFNγ ELISPOT assay was performed using the BD ELISPOT kit reagents and protocol (BD 8 
Biosciences). Briefly, blood or spleen derived cells were seeded at a density of 2.5 x 105/well in 96 9 
well plates and stimulated overnight either with 2 µg/ml of the H-2Kd restricted Influenza NP147-155 10 
(TYQRTRALV) epitope or with 10 µg/ml of concanavalin A (Sigma Chemicals) used as a positive 11 
control. A 139 peptide array (15mers with 11 amino acid overlaps) spanning the entire HA from 12 
influenza virus A/California/7/09 protein (BEI Resources, Manassas, VA, USA; Catalog No. NR-13 
15433) was distributed in ten pools of 14 peptides each and used to identify the reactive epitopes on 14 
splenocytes. Complete medium treated cells were used as negative controls. Spot Forming Cells 15 
(SFC) were counted with an ELISPOT reader (A.EL.VIS, Hannover, Germany) and results expressed 16 
as number of IFNγ secreting cells (spot forming cells, SFC)/106 cells. The samples were scored 17 
positive when a minimum of 50 spots per 106 cells were present and two fold higher than unstimulated 18 
sample. 19 
 20 
Measurement of binding and functional antibodies 21 
Sera were tested for the presence of binding Abs by a standard ELISA. Ninety-six well plates (Greiner 22 
bio-one, Kremsmünster, Austria) were coated with H1N1 A/California/4/09 subunit vaccine (0.2 23 
µg/well of HA) overnight at 4°C. After washing and blocking, serial dilutions of serum from 24 
individual mice were added to wells in duplicate and incubated for 2 hrs at room temperature. The 25 
plates were washed and biotin-conjugated goat anti-mouse IgG (Southern Biotech, Birmingham, AL, 26 
USA) was added to the wells for 2 hrs at room temperature. The plates were washed before the 27 
addition of horse radish peroxidase (HRP)-conjugated streptavidin (AnaSpec, Fremont, CA, USA) 28 
for 30 min at room temperature, followed by the 3,3’5,5-tetramethylbenzidine substrate (SurModics 29 
BioFX, Edina, MN, USA). Endpoint titers were determined as the reciprocal of the highest dilution 30 
giving an absorbance value at least equal to twofold that of background (biological sample from naive 31 
mice). For each group of immunization, results were expressed as mean titer with confidence interval.  32 
Haemagglutination inhibition (HAI) Abs to A/California/7/09 virus were measured, according to 33 
standard procedures (432). Briefly, all sera were treated with receptor-destroying enzyme (RDE, 34 
Sigma Aldrich) to remove non-specific inhibitors of haemagglutination. Serial 2-fold dilutions of 35 
treated sera were mixed with 4 haemagglutinin units of the A/California/7/09 virus and, after 1 h 36 
incubation at room temperature, with 0.5% turkey red blood cells. The HAI titers were expressed as 37 
the reciprocal of the highest dilution of serum that inhibited virus-induced haemagglutination.  38 
The sera were tested by MDCK cell-based microneutralization (MN) assay (443) to titrate influenza 39 
virus-specific neutralizing antibodies. Briefly, all samples were heat-treated at 56°C for 30 min. Two-40 
fold serial dilutions of samples, starting from 1:10 dilution, were performed across the 96-well plates 41 
and then the viral working solution of A/California/07/2009 (H1N1) live virus was added (200 42 
TCID50/100µl),. After incubation of mixture sera-virus at 37°C for 1 h, a cell suspension of 2x105 43 
was added and the plates were incubated at 37°C for 5 days. Each plate was then checked under an 44 
optical microscope to assess the presence of local lesions and cytopathogenic effect (CPE). The 45 
neutralization titer (NT) for each serum was calculated according to the Spearman-Kärber formula.  46 
Since NA plasmid was included during the IDLV preparation and NA protein may be present in 47 
subunit vaccine preparations, Tthe heat-treated sera were also tested by Enzyme-Linked Lectin Assay 48 
(ELLA) (454) to measure the functional anti-neuraminidase (anti-NA) antibodiesAbs. Briefly, serial 49 
2-fold dilutions of treated sera were mixed with antigen A/California/07/2009 (H1N1) treated with 50 





at 37°C overnight (16-18h). After washing the plates, the peanut agglutinin conjugate with peroxidase 1 
(PNA-HRPO) was added and the plates were incubated at room temperature for 2h in the dark. Then 2 
the o-phenylenediamine dihydrochloride (OPD) substrate was added and the plates were incubated at 3 
room temperature for 10 min in the dark. The reaction was stopped by adding 1N H2S04. The Optical 4 
Density (OD) of all the test plates was read at 490 nm. The NA inhibition (NI) titer was expressed as 5 
the reciprocal of the last dilution that results in at least 50% inhibition of the maximum signal. 6 
 7 
Statistical analysis 8 
The temporal trend of antibody response (i.e, ELISA, HAI, MN and ELLA) was analyzed using a 9 
system of piecewise linear equations in order to jointly evaluate the relationships of each outcome at 10 
each time point, allowing for correlated errors. The analysis was conducted in STATA13 (StataCorp 11 
LP, College Station, TX) within a structural equation modelling (SEM) frame work (465, 476). The 12 
log likelihood estimation procedure was used to fit the model to the data. 13 







Production of Integrase Defective Lentiviral Vector (IDLV) delivering Influenza HA 3 
To produce IDLV expressing HA, 293T LentiX cells were transfected with IN defective packaging 4 
plasmid, expressing the proteins required for IDLV assembly and release, the pseudotyping VSV.G-5 
expressing plasmid, essential for IDLV entry into target cells, and HA-expressing lentiviral transfer 6 
vector plasmid, with the aim of pseudotyping the recombinant IDLV particles with the membrane 7 
tethered HA. Importantly, the presence of HA protein on the surface of the transfected cells was 8 
confirmed by flow cytometry and confocal microscopy (Fig. 1A and 1B). However, the recovery of 9 
IDLV in the supernatant of the transfected cells was very low, indicating inhibition of release of IDLV 10 
pseudotyped with HA envelope (Fig. 2A, left column). This was expected since, as with wild type 11 
influenza virus, Neuraminidase (NA) protein is required for release of lentiviral vectors pseudotyped 12 
with influenza HA (17, 18, 487). To improve production of HA-pseudotyped IDLV, we co-13 
transfected plasmids expressing NA protein, required for cleavage of surface sialic acid molecules on 14 
producer cells allowing release of the vector in the supernatant, and human serine transmembrane 15 
protease TMPRSS2 or human airway trypsin (HAT) proteins, mediating proteolytic activation of 16 
influenza HA (18). 17 
 18 
As shown in Figure 2A, recovery of IDLV-HA increased an average of 8-fold in presence of 19 
TMPRSS2 but only 2-fold in the presence of HAT. Importantly, NA was fundamental for IDLV-HA 20 
release, increasing the amount of IDLV recovered in the supernatant an average of 24-fold over the 21 
IDLV produced in the absence of NA expressing plasmid. The inclusion of TMPRSS2 or HAT in 22 
addition to NA protein further improved, although not significantly, vector production (27-fold- and 23 
25-fold, respectively, compared to IDLV produced in the absence of NA and proteases). For 24 
producing concentrated IDLV preparations for immunization, TMPRSS2 was chosen over HAT 25 
protease expressing plasmid since IDLV production was generally higher and more consistent.  26 
To produce IDLV expressing NP, vector was produced as described above and in the Materials and 27 
Methods section, by including a NP-expressing lentiviral transfer vector plasmid and a plasmid 28 
expressing the HA protein for pseudotyping the IDLV produced in the 293T cells. In Figure 2B is 29 
shown a representative western blot (WB) analysis of lysates from concentrated stocks of IDLV 30 
showing the presence of HA protein in all purified IDLV preparations.  31 
 32 
A single immunization with IDLV induces high and persistent levels of binding and antiviral 33 
neutralizing antibodies 34 
To mimic the immunization protocol of the seasonal influenza in humans, mice were given a single 35 
immunization and the immune responses were analyzed at various time points up to 24 weeks. As 36 
positive controls, groups of mice were immunized with H1N1 subunit vaccine alone (HAp) or in 37 
combination with MF59 (HAp+MF59). The schedule of immunization is described in Figure 3A.  38 
Humoral response to H1N1 was assessed initially by ELISA. As shown in Figure 3B, 2 weeks after 39 
the prime all vaccinated animals developed anti-H1N1 IgG antibodies in serum. The titers increased 40 
and persisted in all groups starting from 8 weeks after immunization. The highest titers were 41 
recovered in animals vaccinated with MF59, while the lowest levels were detected in the HAp group. 42 
No significant difference was observed between HAp+MF59 group and IDLV groups. Importantly, 43 
in both groups of IDLV vaccinated animals sustained Abs were induced at significantly higher titers 44 
than HAp alone (p<0.01).  45 
 46 
To assess the recall response, mice were boosted with HAp alone 6 months after the prime. Two 47 
weeks after the immunization with HAp all groups showed a boost in terms of binding Ab titers (Fig. 48 
3B). In particular, IDLV vaccinated animals were able to increase the anti-H1N1 Abs when boosted 49 
with HAp, indicating that immunization with IDLV enables the animals to respond to the HA antigen 50 





weeks after the boost in all vaccinated animals. After the boost the differences between IDLV 1 
immunized animals and HAp group remained statistically significant (p<0.01). Again, no significant 2 
difference in Ab titers between both IDLV groups and the adjuvanted group was seen. 3 
 4 
To assess the functional antibodies, haemagglutination inhibition (HAI) assay and 5 
microneutralization (MN) assay were performed at 8 and 19 weeks post priming and 2 weeks and 18 6 
weeks post boost (Fig. 4). HAI titers were present in all groups at 8 weeks post-immunization and 7 
were still detectable at 19 weeks post priming (Fig. 4A). The response significantly increased after 8 
the boost in all groups. The kinetics of HAI titers mirrored the kinetics of binding Abs, showing the 9 
highest titers in the adjuvant treated group and the weakest ones in the HAp immunized animals. Both 10 
groups of IDLV vaccinated animals showed similar levels of HAI titers (p>0.05), significantly lower 11 
than HAp+MF59 (p<0.05), but significantly higher compared to HAp vaccinated animals (p<0.01). 12 
Interestingly, the MN assay showed absence of neutralizing activity in the HAp alone group of mice 13 
after the prime, while MN titers were always present in both groups of IDLV vaccinated animals (Fig 14 
4B). Again the highest activity was present in serum samples from HAp+MF59 immunized group. 15 
The boost increased the MN titers in all groups, including the HAp immunized animals. 16 
 17 
IDLV induces anti-NA response  18 
Since NA plasmid was included during the IDLV preparation and NA protein is present in subunit 19 
vaccine preparations (498, 5049), we investigated the anti-NA response in all groups of immunized 20 
animals. Serum samples were thus assayed for neuraminidase inhibition (NI) activity. As shown in 21 
Figure 5, both IDLV groups showed a strong NI activity at all indicated time points after the prime 22 
that was significantly boosted after the immunization with HAp. A similar response was detected in 23 
the adjuvant vaccinated group, while the animals vaccinated with HAp alone did not generate 24 
detectable anti-NA response after the prime, showing low NI activity only after the boost. 25 
 26 
IDLV vaccination induces T cell response to HA and NP delivered as transgenes 27 
In order to assess the NP specific CD8-restricted cellular response in mice immunized with IDLV-28 
NP/HA, INFγ ELISPOT was performed using blood cells collected at 4, 12 and 24 weeks after the 29 
prime, stimulated with MHC Class I-restricted NP peptide (Fig. 6A). As expected, a high number of 30 
IFNγ producing T cells was detected in animals vaccinated with IDLV-NP/HA overtime, confirming 31 
a strong and persistent CD8+ T cell response directed to the transgene delivered by IDLV. The NP-32 
specific T cell response was also analyzed in splenocytes at 42 weeks after a single IDLV-NP/HA 33 
immunization further confirming the persistence of transgene-specific IFNγ producing CD8 T cells 34 
(Fig. 6A). 35 
 36 
In order to evaluate the HA specific response, INFγ ELISPOT was also performed in splenocytes 37 
from all groups of mice at sacrifice 18 weeks after the boost (42 weeks after the prime). Ten pools of 38 
15mer peptides spanning the entire HA protein were used and the cumulative mean response against 39 
the HA pools is shown in Figure 6B. HA-specific IFNγ producing cells were detected only in mice 40 
primed with IDLV-HA/HA, while no positive response was observed in mice immunized with HAp 41 
with or without the adjuvant. In particular, pool 1, pool 9 and pool 10 (mean of 165.4, 666.2, 158.1 42 
SFC/106 cells, respectively) were responsible for the HA-specific response.  43 






In this study, we assessed the feasibility of improving the strength of immune response for influenza 3 
vaccination by administering IDLV engineered to express either HA or NP proteins as transgenes, 4 
for induction of T cell responses and to carry HA on the surface of IDLV particles for a concomitant 5 
induction of functional antibodies against influenza virus. 6 
 7 
 8 
Immunization with either HA-pseudotyped IDLV induced functional and durable Ab responses that 9 
were further increased after boosting with H1N1 purified subunit vaccine. This suggests that for 10 
induction of HA-specific Abs, HA protein does not need to be expressed from the IDLV transgene. 11 
Titers were lower or comparable to those obtained after immunization with MF59-adjuvanted H1N1 12 
purified subunit vaccine, which we used as a gold standard for the induction of a strong and effective 13 
antibody response against influenza virus in mice. In particular, persistent HAI titers and anti-HA 14 
neutralizing Abs against homologous influenza virus strain were detected throughout the time course 15 
after the prime and were further increased after the boost. Of note, mice immunized with both IDLV-16 
HA/HA and IDLV-NP/HA induced functional anti-NA Abs, which were detected after the prime and 17 
increased after the boost, as measured by the NI assay. Titers were comparable to those obtained after 18 
immunization with MF59-adjuvanted H1N1 purified subunit vaccine, but significantly higher 19 
compared to HAp immunized animals. NA activity is required for the release of HA-pseudotypes of 20 
IDLV from producer cells and a plasmid expressing the NA protein was included during preparation 21 
of IDLV for enabling vector production, as described in other settings (18). Although NA-specific 22 
Abs may not effectively prevent viral infection in humans, they may inhibit virus spread and reduce 23 
the severity of disease (510, 521), and a recent report provided strong evidence that NI titers correlated 24 
more significantly with reduced disease severity in a healthy volunteer challenge study performed 25 
with a wild-type influenza A challenge virus (532). Additional characterization of IDLV vaccine-26 
induced functional antibodies, such as mapping of broadly neutralizing antibodies directed to the stem 27 
region of HA, will provide further information on the value of our platform. 28 
 29 
While induction of HA-specific antibodies represents the primary strategy for prevention and control 30 
of influenza after vaccination in humans (3653), CD8+ T-cell responses against influenza virus 31 
proteins are often induced and may contribute to heterosubtypic protection (54-56). Tthe highly 32 
conserved viral NP has become an important focus for the development of broad, cross-protective or 33 
“universal” influenza vaccines. NP specific cell-mediated responses have been shown to be protective 34 
against homologous and heterosubtypic influenza virus challenge in animal models (13, 54-57) and 35 
may help in reducing disease severity through enhancing viral clearance in humans (30, 58). For this 36 
reason, we also evaluated T cell response induced by IDLV over time. In our previous work (13) we 37 
assessed the ability of IDLV-NP to induce protective immunity using different routes of 38 
immunization. In particular, we demonstrated that intranasal administration of IDLV-NP was more 39 
efficient than intramuscular immunization in protecting mice from influenza virus challenge. 40 
Although the protection from influenza challenge in mice can be achieved in presence of NP-specific 41 
T cell responses, this correlation has not been confirmed in humans, where the T cell responses 42 
directed toward conserved proteins may instead help in controlling the disease symptoms (28-30). To 43 
further improve the strength of our vaccine and to render the platform more suitable for human use, 44 
in the present work we focused on the development of a new vector strategy for expressing influenza 45 
antigens not only as transgenes but also as surface molecules. Here we demonstrated that the multi 46 
antigen IDLV-based influenza vaccine induced durable and functional immune responses in terms of 47 
NP or HA transgene-specific T cell responses and protective antibodies directed towards the surface 48 
proteins HA and NA.Overall our results indicate that immunization with IDLV-HA/HA and IDLV-49 
NP/HA induced cell-mediated immune responses against the respective transgene. In particular, NP-50 
specific CD8-restricted cellular responses, as measured by INFγ ELISPOT, were present and 51 




maintained up to 42 weeks after a single immunization in mice immunized with IDLV-NP/HA. 1 
Similarly, HA-specific IFNγ producing cells were detected in mice immunized with IDLV-HA/HA, 2 
but not in mice immunized with HAp with or without MF59 adjuvant.  3 
 4 
Other approaches have been tested for delivering multiple antigens for inducing cellular and humoral 5 
immunity. As an example, a recent report using Adenovirus and MVA delivering Influenza NP, M1 6 
and HA antigens in a prime-boost regimen showed induction of immune responses against the 7 
delivered antigens and protection after challenge (59). The approach described in our report shows 8 
that multivalent IDLV efficiently induce a prolonged cellular immune response due to expression of 9 
the vectored HA and NP transgenes from episomal DNA circles, as described in several settings (1, 10 
2), and functional humoral responses to HA and NA proteins. 11 
 12 
Previous work has shown that recombinant influenza vaccines containing insect cell-expressed virus-13 
like particles (VLPs) displaying H1N1 may constitute a promising vaccination approach (60). 14 
Pseudotype-based influenza genes delivery represents an alternative to successfully express HA in 15 
mammalian cells providing an efficacious vaccine when tested in chickens and mice (61, 62). More 16 
recently, Venereo-Sanchez and co-workers showed that HIV-Gag based VLP displaying H1N1 17 
induced a sustained immune response which provided full protection after lethal challenge with the 18 
homologous virus strain in mice (63). Of note, IDLVs used in our report were pseudotyped with 19 
VSV.G glycoprotein which may also contribute to the strength of the IDLV-induced immune 20 
responses by increasing the tropism of the vector. In fact, it has been shown that HIV virus-like 21 
particles (VLP) pseudotyped with VSV-G are more immunogenic compared to VLP that lacked VSV-22 
G, in a monkey model of immunization (64) and that VSV-G-pseudotyped LV can adhere to 23 
transduced cells for a substantial amount of time, thus leading to additional cycles of transduction 24 
(65-67). These are potentially important advantages for exploiting recombinant IDLV pseudotyped 25 
with VSV.G and/or other heterologous viral proteins.  26 
 27 
In conclusion, our study highlights the potential for IDLV to be developed for use as a novel multi-28 
antigen vaccine platform against influenza virus. Combination of NP, HA and NA antigens in the 29 
same IDLV results in a more comprehensive and functional immune response, which may be 30 
beneficial to prevent and/or control influenza virus infection. 31 
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FIGURES LEGENDS 1 
 2 
Figure 1. Analysis of HA expression. 293T Lenti-X cells were transfected with HA expressing 3 
plasmid and stained at 24 hours post-transfection for detection of HA on the plasma membrane as 4 
described in Materials and Methods. Cells were fixed and expression of HA was quantitatively 5 
measured by flow cytometry (A) or observed by CLSM (B). (A) The percentage of HA-expressing 6 
cells is indicated. The overlay line (green) represents the fluorescence distribution of cells stained 7 
only with the secondary Ab. (B) Images represent single central optical sections (a-c) and a 3D 8 
reconstruction (d). Nuclei are colored in blue by DAPI staining and green color represents membrane 9 
associate HA protein. Scale bars, 8 µm. Untransfected cells (a) were used as negative control. Results 10 
from one representative experiment are shown for each analysis. 11 
 12 
Figure 2. Production and validation of IDLV pseudotyped with HA. (A) Reverse transcriptase 13 
(RT) activity of IDLV expressing HA. Vectors were produced as described in Materials and Methods 14 
and in the presence of plasmids expressing TMPRSS2, HAT or NACal09, as indicated in the graph. 15 
Data are expressed as the mean result from three independent experiments. The error bars represent 16 
the standard errors of the mean. (B) Western blot (WB) of lysates from concentrated stocks of IDLV 17 
pseudotyped with HA showing incorporation of HA into IDLV. Note that IDLVs were produced in 18 
the presence of TMPRSS2 protease, resulting in the cleavage of HA0 to produce HA1 (not visualized 19 
here) and HA2. HA protein (HAp*, purified hemagglutinin vaccine subunit from influenza virus 20 
H1N1 A/California/7/2009) and IDLV-GFP were used as positive and negative control respectively.  21 
 22 
Figure 3. Immunization schedule and kinetics of anti-H1N1 binding Abs. (A) Immunization 23 
schedule. CB6F1 mice (4 mice/group) were primed once intramuscularly with IDLV expressing HA 24 
and pseudotyped with HA (IDLV- HA/HA), IDLV expressing NP and pseudotyped with HA (IDLV-25 
NP/HA), HA protein (*purified hemagglutinin vaccine subunit from influenza strain H1N1 26 
A/California/7/2009) in combination with MF59 as an adjuvant (HAp+MF59), HA protein alone 27 
(HAp) or left untreated (Naive). All groups except for naive were boosted with HAp at 24 weeks after 28 
the prime. Blood was collected at several time points in order to perform ELISA and IFNγ ELISPOT 29 
assays. (B) Kinetics of serum anti-H1N1 IgG Abs. Serum samples from all groups were collected at 30 
the indicated time points after the prime and were assayed for the presence of anti-H1N1 IgG by 31 
ELISA. Results are expressed as predicted mean endpoint titers. The predicted mean values at each 32 
time point were estimated by a system of piecewise linear regressions including all antibody 33 
measurements within a structural equation modelling (SEM) frame work. Error bars indicate the 95% 34 
confidence interval. Asterisks indicate significant differences between groups at all the analyzed time 35 
points; ** p value<0.01.  36 
 37 
Figure 4. Kinetics of functional anti-HA Abs. Serum samples from all groups were collected at the 38 
indicated time points after the prime and were assayed for the presence of neutralizing Abs against 39 
A/California/7/09 virus, by HAI assay (A) and MN assay (B). Results are expressed as predicted 40 
mean endpoint titers. The predicted mean values at each time point were estimated by a system of 41 
piecewise linear regressions including all antibody measurements within a structural equation 42 
modelling (SEM) frame work. Error bars indicate the 95% confidence interval. Asterisks indicate 43 
significant differences compared to the HAp group, at the indicated time points; **p<0.01; *p<0.05. 44 
 45 
Figure 5. Kinetics of functional anti-NA Abs. Serum samples from all groups were collected at the 46 
indicated time points after the prime and were assayed for the presence of anti-NA Abs by ELLA 47 
assay (see Materials and Methods). Results are expressed as predicted mean endpoint titers. The 48 
predicted mean values at each time point were estimated by a system of piecewise linear regressions 49 





bars indicate the 95% confidence interval. Asterisks indicate significant differences compared to the 1 
HAp group at all the analyzed time points; ** p value<0.01.  2 
 3 
Figure 6. Analysis of antigen-specific T cells response. (A) Kinetics of NP-specific T cell response 4 
in mice immunized with IDLV-NP/HA. IFNγ ELISPOT was performed using blood cells collected 5 
at 4, 12 and 24 weeks post prime and splenocytes collected at 42 weeks post prime. Results are 6 
expressed as mean spot forming cells (SFC) per 106 cells. Cells were stimulated overnight with the 7 
MHC I-restricted epitope derived from NP protein sequence (black bars) or left untreated (white bars). 8 
Error bars indicate the standard deviation among mice of the same group. (B) Analysis of HA-specific 9 
T cell response in immunized mice. IFNγ ELISPOT was performed using splenocytes collected at 42 10 
weeks post prime, using 10 pools of 15mers spanning the full lenght of HA protein, as described in 11 
Materials and Methods. Results are expressed as cumulative mean spot forming cells (SFC) per 106 12 
cells for each pool among mice of the same indicated group.  13 
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